Chris is President and Chief Executive Officer of Aprea Therapeutics AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies. He is a Board Director of Integra Life Sciences and a member of its Audit Committee and Chair of its Finance Committee.
Chris was Chief Executive Officer of Novira Therapeutics Inc., a privately held biopharmaceutical company, until its acquisition by Johnson & Johnson in December 2015.
Chris was previously Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., a specialty pharmaceutical company, prior to its sale in July 2013 to AstraZeneca for up to $445 million. He was EVP and CFO at NRG Energy from March 2010 to September 2011. Chris joined Medarex Inc., in 2000 and helped it grow to become a leading pharmaceutical development company and, as Senior Vice President Administration and Chief Financial Officer, played a lead role in the negotiations for Bristol-Myers Squibb Co.’s $2.4 billion acquisition of Medarex in September 2009 and the subsequent merger-integration process.
Prior to Medarex, Chris served as Managing Director and head of the European Corporate Funding Group at Merrill Lynch in London and also held various capital markets and corporate finance positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co.
Christian received an A.B. from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.
Chair of the Audit Committee
Member of the Science & Policy Committee